Decline in financial settlements with U.S. Big Pharma -report

WASHINGTON, March 31 (Reuters) - The amount of money big U.S. pharmaceutical manufacturers have paid to settle charges for violating federal health care laws has declined sharply in recent years, prompting a non-profit watchdog group to call for an increase in enforcement efforts.